Discussion
Denecimig (Mim8), an investigational antibody therapy being developed by Novo Nordisk, continued to maintain low bleeding rates in children, adolescents, and adults with hemophilia A, with safety findings consistent with earlier studies, regardless of inhibitor status or dosing schedule. That’s according to interim data from FRONTIER4 (NCT05685238), an…